AGC Biologics to build new facility in Japan
AGC Biologics has announced the establishment of a new manufacturing site at the AGC Yokohama Technical Center in Japan.
AGC Biologics has announced the establishment of a new manufacturing site at the AGC Yokohama Technical Center in Japan.
Lavipharm has signed an agreement with Sanofi to acquire the pharmaceutical product, Flagyl, for the Greek market, for an undisclosed sum.
Aurinia Pharmaceuticals’ collaboration partner Otsuka Pharmaceutical has submitted a new drug application (NDA) to the Japanese Ministry of Health, Labour and Welfare for voclosporin to treat lupus nephritis (LN).
BridgeBio Pharma has entered into a strategic partnership with National Resilience (Resilience) for the manufacturing and advancement of two investigational gene therapies, BBP-812 and BBP-631.
German generic drug manufacturer STADA Group has agreed to acquire a portfolio of well-established consumer healthcare brands from biopharmaceutical firm Sanofi to expand its European Consumer Healthcare portfolio.
Danaher, a science and technology company, has agreed to acquire biotech firm Aldevron from EQT Private Equity for an enterprise value of $9.bn.
Biopharmaceutical company SciNeuro Pharmaceuticals has signed an exclusive license agreement with Eli Lilly and Company for the development and commercialisation of alpha-synuclein targeted antibody therapies in Greater China.
Biogen and Bio-Thera Solutions have entered into a commercialisation and license agreement for the development, manufacturing and commercialisation of BAT1806.
Piramal Pharma (PPL), a subsidiary of Piramal Enterprises, has agreed to acquire 100% stake in Indian peptide APIs manufacturer Hemmo Pharmaceuticals, for $105.6m (INR7.75bn).
Anima Biotech has announced its new strategic collaboration deal with Takeda Pharmaceutical Company for the discovery and development of new medicines to combat genetically defined neurological diseases.